Pharmacokinetics and safety of the two oral cefaclor formulations in healthy chinese subjects in the fasting and postprandial states
We conducted a phase I bioequivalence trial in healthy Chinese subjects in the fasting and postprandial states. The goal of this trial was to compare the pharmacokinetics and safety of the test preparation Cefaclor granule (Disha Pharmaceutical Group Co., Ltd.) and the reference preparation Cefaclor...
Main Authors: | Xinyao Qu, Qiaohuan Deng, Ying Li, Peng Li, Guangwen Liu, Yanli Wang, Zhengzhi Liu, Shuang Yu, Yang Cheng, Yannan Zhou, Jiahui Chen, Qing Ren, Zishu Yu, Zhengjie Su, Yicheng Zhao, Haimiao Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1012294/full |
Similar Items
-
Population Pharmacokinetic Analysis of Cefaclor in Healthy Korean Subjects
by: Seung-Hyun Jeong, et al.
Published: (2021-05-01) -
HLA-DRB1 is associated with cefaclor-induced immediate hypersensitivity
by: So-Young Park, MD, PhD, et al.
Published: (2024-05-01) -
Cefaclor as a first-line treatment for acute uncomplicated cystitis: a retrospective single-center study
by: Dai Koguchi, et al.
Published: (2020-04-01) -
Matrine reverses the resistance of Haemophilus parasuis to cefaclor by inhibiting the mutations in penicillin-binding protein genes (ftsI and mrcA)
by: JingChao Zhao, et al.
Published: (2024-03-01) -
Pharmacokinetics and bioequivalence of sunitinib and Sutent® in Chinese healthy subjects: an open-label, randomized, crossover study
by: Yanli Wang, et al.
Published: (2023-11-01)